Review Article
The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)
Table 4
Current stage of vaccines and their manufacturer.
| | Types of vaccine | Vaccine name | Phase | Manufacturer | Country of origin |
| | mRNA vaccine | mRNA1273 | Phase 3 | Moderna | US | | Comirnaty | Phase 2/3 | Pfizer-BioNtech | Multinational | | Protein subunits | EpiVacCorona | Phase 3 | Vector Institute | Russia | | NUX-CoV2373 | Phase 3 | Novavax | Australia | | Inactivated virus | BBIBP-CorV | Phase 3 | Sinopharm | China | | CoronaVac | Phase 3 | Sinovac | China | | Name not announced | Phase 3 | Sinopharm-Wuhan | China | | Covaxin | Phase 3 | Bharat Biotech | India | | DNA-based vaccine | Convidecia | Phase 3 | CanSino | China | | JNJ-78436735 | Phase 3 | Johnson & Johnson | The Netherlands, US | | Sputnik V | Phase 3 | Gamaleya | Russia | | Covishield (AZD1222) | Phase 2/3 | Oxford-AstraZeneca | UK |
|
|
